These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6503214)

  • 61. Preventing the contact dermatitis caused by a transdermal clonidine patch.
    McChesney JA
    West J Med; 1991 Jun; 154(6):736. PubMed ID: 1877221
    [No Abstract]   [Full Text] [Related]  

  • 62. New indices in the evaluation of clonidine transdermal therapy of hypertension.
    de Leonardis V; de Scalzi M; Becucci A; Lusini C; Cinelli P
    Int J Clin Pharmacol Res; 1989; 9(5):341-5. PubMed ID: 2625373
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance.
    Weidler D; Wallin JD; Cook E; Dillard D; Lewin A
    J Clin Pharmacol; 1992 May; 32(5):444-9. PubMed ID: 1587962
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical efficacy of oral-transdermal clonidine combinations during the perioperative period.
    Segal IS; Jarvis DJ; Duncan SR; White PF; Maze M
    Anesthesiology; 1991 Feb; 74(2):220-5. PubMed ID: 1990896
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rate and extent of absorption of clonidine from a transdermal therapeutic system.
    Toon S; Hopkins KJ; Aarons L; Rowland M
    J Pharm Pharmacol; 1989 Jan; 41(1):17-21. PubMed ID: 2565958
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics of transdermally delivered clonidine.
    MacGregor TR; Matzek KM; Keirns JJ; van Wayjen RG; van den Ende A; van Tol RG
    Clin Pharmacol Ther; 1985 Sep; 38(3):278-84. PubMed ID: 4028622
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of chronic hypertension with intravenous enalaprilat and transdermal clonidine.
    Zawaideh MA; Duncan B; Joseph MW; Dixit MP
    Pediatr Nephrol; 2001 Jan; 16(1):85-6. PubMed ID: 11198612
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Transdermal delivery of the alpha 2-agonist clonidine does not alter airways responses to inhaled histamine or methacholine.
    Scott GC; Chu CS; Braun SR
    Chest; 1991 Oct; 100(4):1035-8. PubMed ID: 1914554
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS.
    Frishman WH; Sherman D; Feinfeld DA
    Cardiol Clin; 1987 Nov; 5(4):703-16. PubMed ID: 3331321
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical pharmacokinetics of clonidine.
    Lowenthal DT; Matzek KM; MacGregor TR
    Clin Pharmacokinet; 1988 May; 14(5):287-310. PubMed ID: 3293868
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low allergenicity of clonidine impedes studies of sensitization mechanisms in guinea pig models.
    Scheper RJ; von Blomberg BM; de Groot J; Goeptar AR; Lang M; Oostendorp RA; Bruynzeel DP; van Tol RG
    Contact Dermatitis; 1990 Aug; 23(2):81-9. PubMed ID: 2209009
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antihypertensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously hypertensive rats.
    Ishii R; Naruse T; Tagawa T; Yamahata T; Dote S; Hamada K; Ishida T; Funabiki K; Namba K
    Arch Int Pharmacodyn Ther; 1994; 327(3):294-308. PubMed ID: 7848013
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Transdermal clonidine: therapeutic considerations.
    Sica DA; Grubbs R
    J Clin Hypertens (Greenwich); 2005 Sep; 7(9):558-62. PubMed ID: 16227779
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antihypertensive effects of a new transdermal delivery system for clonidine in genetic and experimental hypertensive rats.
    Ishii R; Tagawa T; Ishida T; Naruse T
    Arzneimittelforschung; 1996 Mar; 46(3):261-8. PubMed ID: 8901146
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of transdermal clonidine on the endocrine responses to insulin-induced hypoglycemia in essential hypertension.
    Guthrie GP; Kotchen TA; Van Loon GR
    Clin Pharmacol Ther; 1989 Apr; 45(4):417-23. PubMed ID: 2649299
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Utility of a transdermal delivery system for antihypertensive therapy. Part 1.
    Sclar DA; Skaer TL; Chin A; Okamoto MP; Gill MA
    Am J Med; 1991 Jul; 91(1A):50S-56S. PubMed ID: 1907801
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rebound hypertension after discontinuation of transdermal clonidine.
    Schmidt GR; Schuna AA
    Clin Pharm; 1988 Oct; 7(10):772-4. PubMed ID: 3233898
    [No Abstract]   [Full Text] [Related]  

  • 79. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial.
    Ornish SA; Zisook S; McAdams LA
    Arch Intern Med; 1988 Sep; 148(9):2027-31. PubMed ID: 3046542
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clonidine transdermal system for treatment of spasticity in spinal cord injury.
    Weingarden SI; Belen JG
    Arch Phys Med Rehabil; 1992 Sep; 73(9):876-7. PubMed ID: 1514897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.